Kathryn B. Alguire

Palbociclib in Patients With Non–Small-Cell Lung Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study

Eugene R. Ahn, Pam K. Mangat, Elizabeth Garrett‐Mayer et al. · JCO Precision Oncology · 2020 · 69 citations

Medicine, Oncology, Pharmacology +16

A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers

Johanna C. Bendell, Ahmed Zakari, Evan Lang et al. · Cancer Investigation · 2016 · 17 citations

Medicine, Oncology, Pharmacology +15

Bevacizumab, pertuzumab, and sandostatin for patients (pts) with advanced neuroendocrine cancers (NET).

Irfan Firdaus, Kent C. Shih, Ahmed Zakari et al. · Journal of Clinical Oncology · 2012 · 12 citations

Medicine, Pharmacology, Pharmacotherapy +15

Palbociclib (P) in patients (pts) with non-small cell lung cancer (NSCLC) with <i>CDKN2A</i> alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Eugene R. Ahn, Pam K. Mangat, Elizabeth Garrett‐Mayer et al. · Journal of Clinical Oncology · 2019 · 10 citations

Medicine, Oncology, Pharmacology +17